Category: Pharma Industry

News Alert

Sandoz Is 28th Drugmaker to Adopt 340B Contract Pharmacy Restrictions

November 1, 2023 Tom Mirga, Editor at Large Views

Drugmaker Sandoz, a Novartis spin-off, became the 28th pharmaceutical company to implement 340B contract pharmacy restrictions.

Generic and biosimilar drugmaker Sandoz today became the 28th pharmaceutical company to place conditions on 340B pricing involving drug shipments [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GSK Loosens 340B Contract Pharmacy Restrictions in Arkansas and Louisiana

October 31, 2023 William Newton, Associate Editor/Senior Writer Views

Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.

GlaxoSmithKline (GSK) today became the fifth drug manufacturer to loosen or end its 340B contract pharmacy restrictions in Arkansas and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Provider-Genentech Lobbying Group Boosts Spending, Adds Members

October 26, 2023 Tom Mirga, Editor at Large Views

More than 360 firms reported lobbying on the 340B program between July 1 and Sept. 30.

Genentech, Sanford Health, and Carolina Health Centers’ 340B reform group, 340B Working Table, spent $110,000 on lobbying and gained eight [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

GSK Adds Drug to Contract Pharmacy Restriction List

October 26, 2023 Rich Daly, Editor in Chief Views

Senderra Rx will no longer dispense GlaxoSmithKline’s asthma drug, Nucala.

GlaxoSmithKline (GSK) recently restricted 340B pricing on Jesduvroq, an anemia treatment, when providers dispense it through contract pharmacies. GSK contractor [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Biocon Announces New NDC for its Lantus Biosimilar

October 26, 2023 Tom Mirga, Editor at Large Views

Biocon has added a new national drug code for its insulin biosimilar, the drugmaker recently notified 340B providers.

Indian biopharmaceutical manufacturer Biocon Biologics has notified 340B covered entities about a new national drug code (NDC) for insulin glargine-yfgn, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Genentech Asks Hospitals to Check 340B Split-Billing Software Settings

October 24, 2023 Tom Mirga, Editor at Large Views

Genentech gave advanced notice to 340B hospitals that the drugmaker would implement 340B contract pharmacy restrictions on May 1.

Drug manufacturer Genentech has asked health systems and hospitals about possible 340B program compliance violations involving split-billing software settings. Staff [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Teva Adds Drug to Hospital Contract Pharmacy Restriction Policy

October 24, 2023 Rich Daly, Editor in Chief Views

Drugmaker Teva recently added its medication Austedo to its list of drugs under 340B contract pharmacy restrictions for hospitals.

Drug manufacturer Teva this week added a drug to the hospital contract pharmacy restrictions it first implemented in June. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Dispute Resolution Final Rule Enters Last Stage of Regulatory Review

October 19, 2023 Rich Daly, Editor in Chief Views

HRSA plans to host a webinar for federal grantees in the days leading up to the 2024 340B recertification period.

A final rule to implement the 340B administrative dispute resolution (ADR) process arrived this week at the last stage of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Five More Providers Owe Drugmakers 340B Repayment: Audits

October 19, 2023 Rich Daly, Editor in Chief Views

HRSA confirmed it will end a pandemic-era waiver program that allowed 340B drug use in certain offsite hospital locations.

A total of 16 covered entities (CEs) owe repayment to drugmakers, five more than reported a month ago, according to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Most 340B DSH Hospitals Provide Below-Average Charity Care, Says Analysis Backed by Critics

October 19, 2023 Rich Daly, Editor in Chief Views

Bob Dold, a spokesperson for AIR340B, said the 340B program "has not translated into a stronger safety-net” after a drug industry backed analysis found 340B DSH hospitals provide below-average charity care.

The majority of 340B disproportionate share hospitals (DSH) provide charity care at lower rates than the national hospital average, found [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

News Alert

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live